Journal of Gastrointestinal & Digestive System
Open Access

Abstract

Hepatocellular Carcinoma (HCC) is increasing worldwide and particularly in Egypt, where the prevalence of hepatitis C viral (HCV) infection, a well-established HCC risk factor, is the highest in the world. Direct-acting antivirals (DAAs) have completely changed the panorama of hepatitis C due to their high efficacy and optimal safety profile. The impact of DAAbased treatment on the incidence of HCC in patients with cirrhosis and particularly on the incidence of HCC recurrence after successful curative treatment has emerged as a controversial issue with potential clinical implications. As Egypt achieved the highest number (>1.5 million) of treated patients by DAAs globally up till now, it is so important to evaluate its situation in this issue. The talk will highlight on the following items: Discrepancy regarding the occurrence and recurrence of HCC, highlight on some Egyptian studies and possible factors contributing to increased HCC incidence/recurrence by DAAs.

Biography

M A Ezzel Arab is a Professor of Internal Medicine and Hepatology. He is the Founder of Intervention and Hepatoma Unit at the National Hepatology and Tropical Medicine Research Institute (NHTMRI) since 2007. He is a member of the steering committee which put the Egyptian guidelines for HCC (2011) which was sponsored by the Egyptian Society of Liver Cancer (ESLC).

E-mail: ezz2006arab@hotmail.com